Linking Evidence and Value Strategies with the Right Stakeholder

Presented by

Paul Just, Senior Principal, Medical Device Health Economics, Commercialisation and Outcomes

About this talk

In these days of austerity, a new healthcare intervention, defined as a drug, medical device, procedure, program, or service, must establish a robust and credible value proposition before or soon after its introduction into mainstream practice. Various healthcare stakeholders have different requirements for and definitions of value. Satisfying their demands is paramount to an intervention’s success and results in more favourable pathways to rapid adoption and market access. Join us as we discuss an approach to evidence-generation strategies in drug and medical device development that enables integrated teams to develop and implement targeted and effective value propositions. Get Insights on: Development of stakeholder value maps as a guide for evidence development Encouraging interdisciplinary collaborations to define differentiating value Prioritization of stakeholders as customers for robust evidence Conceptualizing a stakeholder targeted evidence planning process Speakers: Paul Just, Senior Principal, Medical Device Health Economics, Commercialisation and Outcomes & Sarah Clifford, Senior Principal, Clinical Outcomes Assessments, Commercialisation and Outcomes

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (35)
Subscribers (484)
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges when it comes to developing their drug or device. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.